Klin Farmakol Farm. 2025;39(3):155-159 | DOI: 10.36290/far.2025.058

Betablockers in the treatment of heart rhythm disorders

Dominik Broniš, Irena Andršová, Tomáš Novotný
I. interní kardiologická klinika FN Brno a LF MU, Brno

Beta-blockers represent a fundamental component in the treatment of cardiac arrhythmias due to their ability to suppress the effects of the sympathetic nervous system and stabilize heart rhythm. They are primarily used for heart rate control in atrial fibrillation, and they also reduce the risk of ventricular arrhythmias and sudden cardiac death, particularly in patients with ischemic heart disease or heart failure. Thanks to their long-established efficacy, good tolerability, and favorable impact on survival, beta-blockers maintain a strong position in clinical practice. Advances in personalized medicine and genetic profiling of patients further open the door to more targeted and effective use of these agents in modern arrhythmology.

Keywords: beta-blockers, arrhythmia, sympathetic nervous system, beta adrenergic receptors.

Accepted: October 23, 2025; Published: October 30, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Broniš D, Andršová I, Novotný T. Betablockers in the treatment of heart rhythm disorders. Klin Farmakol Farm. 2025;39(3):155-159. doi: 10.36290/far.2025.058.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997-4126. Available from: https://doi.org/10.1093/eurheartj/ehac262. Go to original source... Go to PubMed...
    2. Oliver E, Mayor F Jr, D'Ocon P. Beta-blockers: Historical Perspective and Mechanisms of Action. Rev Esp Cardiol (Engl Ed). 2019;72(10):853-862. Available from: https://doi.org/10.1016/j.rec.2019.04.006. Go to original source... Go to PubMed...
    3. Vítovec J, Špinarová M. Betablokátory a kardiovaskulárni onemocnění - kontroverze 2023. Klinická farmakologie a farmacie. 2024;38(1):5-8. Available from: https://doi.org/10.36290/far.2024.001. Go to original source...
    4. Grandi E, Ripplinger CM. Antiarrhythmic mechanisms of beta blocker therapy. Pharmacol Res. 2019;146:104274. Available from: https://doi.org/10.1016/j.phrs.2019.104274. Go to original source... Go to PubMed...
    5. Wołowiec Ł, Grześk G, Osiak J, et al. Beta-blockers in cardiac arrhythmias - Clinical pharmacologist's point of view. Front Pharmacol. 2023;09:13:1043714. Available from: https://doi.org/10.3389/fphar.2022.1043714. Go to original source... Go to PubMed...
    6. Kotadia ID, Williams SE, O'Neill M. Supraventricular tachycardia: An overview of diagnosis and management. Clin Med (Lond). 2020;20(1):43-47. Available from: https://doi.org/10.7861/clinmed.cme.20.1.3. Go to original source... Go to PubMed...
    7. Kowey PR, Friehling TD, Marinchak RA. Electrophysiology of beta blockers in supraventricular arrhythmias. Am J Cardiol. 1987;60(6):32D-38D. Available from: https://doi.org/10.1016/0002-9149(87)90706-5. Go to original source... Go to PubMed...
    8. Katritsis DG, Josephson ME. Classification, Electrophysiological Features and Therapy of Atrioventricular Nodal Reentrant Tachycardia. Arrhythm Electrophysiol Rev. 2016;5(2):130-135. Available from: https://doi.org/10.15420/AER.2016.18.2. Go to original source... Go to PubMed...
    9. Buttner R. Atrioventricular Re-entry Tachycardia (AVRT). Life in the fastlane 2022 [online]. Available from: https://litfl.com/atrioventricular-re-entry-tachycardia-avrt/.
    10. Ioannou A. Atrial fibrillation with ventricular pre-excitation: a diagnosis that must not be missed. Archives of Medical Case Reports and Case Study. 2022;5(4):01-03. Available from: https://doi.org/10.31579/2692-9392/106. Go to original source...
    11. Pellman J, Sheikh F. Atrial fibrillation: mechanisms, therapeutics, and future directions. Compr Physiol. 2015;5(2):649-665. Available from: https://doi.org/10.1002/cphy.c140047. Go to original source... Go to PubMed...
    12. Mazzanti A, Kukavica D, Trancuccio A, et al. Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers. JAMA Cardiol. 2022;7(5):504-512. Available from: https://doi.org/10.1001/jamacardio.2022.0219. Go to original source... Go to PubMed...
    13. Aggarwal A, Stolear A, Alam MM, et al. Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies. J Clin Med. 2024;13(6):1781. Available from: https://doi.org/10.3390/jcm13061781. Go to original source... Go to PubMed...
    14. Ackerman MJ, Prior SG, Dubin AM, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? Heart Rhythm. 2017;14(1):e41-e44. Available from: https://doi.org/10.1016/j.hrthm.2016.09.012. Go to original source... Go to PubMed...
    15. Groffen AJ, Bikker H, Christiaans I. Long QT Syndrome Overview. In GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle 1993. 2003 Feb 20 [updated 2024 Mar 21]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1129/.
    16. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol. 2011;57(1):51-59. Available from: https://doi.org/10.1016/j.jacc.2010.07.038. Go to original source... Go to PubMed...
    17. Tamirisa KP, Elkayam U, Briller JE, et al. Arrhythmias in Pregnancy. JACC Clin Electrophysiol. 2022;8(1):120-135. Available from: https://doi.org/10.1016/j.jacep.2021.10.004. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.